INMB Q2 2022 Earnings — INmune Bio, Inc. Revenue & Financial Results | Market Cap Arena

INMBINmune Bio, Inc.

$37M

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$16,000

Gross Profit

$16,000100.0% margin

Operating Income

-$6M-39925.0% margin

Net Income

-$7M-42737.5% margin

EPS (Diluted)

$-0.41

QoQ Revenue Growth

-90.2%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$5M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$88M

Total Liabilities

$18M

Stockholders' Equity

$70M

Cash & Equivalents

$61M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$16,000	$0	—
Gross Profit	$16,000	$0	—
Operating Income	-$6M	-$7M	+2.5%
Net Income	-$7M	-$7M	-2.7%